<DOC>
	<DOCNO>NCT02564380</DOCNO>
	<brief_summary>A Phase II Randomized , Double-Blind , Placebo-Controlled Study Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy Patients Metastatic Squamous - Non-Small Cell Lung Cancer ( sNSCLC ) .</brief_summary>
	<brief_title>Study Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy Patients With Metastatic Squamous - Non-Small Cell Lung Cancer ( sNSCLC )</brief_title>
	<detailed_description>Patients squamous non-small cell lung cancer ECOG 0-1 receive first-line therapy Cis-/Carboplatin least 2 cycle least Complete Response ( CR ) / Partial Response ( PR ) / Stable Disease ( SD ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) v 1.1 randomize either Arm A Pembrolizumab Arm B Placebo maximum 2 year progressive disease unacceptable toxicity . The aim investigate efficacy Pembrolizumab vs. placebo term progression-free survival patient metastatic squamous , non-small cell lung cancer . Furthermore evaluate tumor response , survival , tolerability safety well quality life patient receive Pembrolizumab .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Male female patient , age ≥ 18 year 2 . Signed informed consent 3 . Ability comply protocol duration study , include hospital visit treatment schedule followup visit examination 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 5 . At least one measurable tumor lesion accord RECIST 1.1 6 . Histologically cytologically confirm diagnosis stage IV ( AJCC Version 7 ) squamous nonsmall cell lung carcinoma 7 . Complete response , partial response stable disease least 2 cycle firstline chemotherapy cisplatin carboplatin 8 . Last administration platinum base firstline chemotherapy ≤ 5 +/ 1 week ( ) prior first dose study treatment 9 . Tumor specimen firstline chemotherapy available immunohistochemistry ( IHC ) PDL1 central laboratory . Tumor specimen must tumor block precut slide . 10 . Adequate bonemarrow organ function : Absolute neutrophil count ≥ 1.5 x 10^9/L Thrombocytes ≥ 100 x 10^9/L Hemoglobin ≥ 9 g/dL International Normalized Ratio ( blood clotting time ) ( INR ) ≤ 1.5 Partial Thromboplastin Time ( PPT ) ≤ 1.5 x upper limit last 7 day therapy Bilirubin &lt; 1.5 x Upper Limit Normal ( ULN ) Aspartate aminotransferase ( ( AST ( GOT ) ) Alanine aminotransferase ( ( ALT ) ( GPT ) ) &lt; 3 x ULN ( 5 x ULN case liver metastasis ) Creatinine ≤ 1.5 x upper limit creatinine clearance ≥ 45 mL/min ( first line chemotherapy ) 11 . In female patient childbearing potential ( i.e . undergo surgical sterilization hysterectomy , bilateral tubal ligation , bilateral oophorectomy postmenopausal least 24 consecutive month ) , negative pregnancy test screen 12 . Female patient childbearing potential male patient female partner childbearing potential must agree use 2 adequate barrier method contraception study treatment 120 day last administration study drug Patients follow eligible study : 1 . Concurrent treatment experimental drug participation another clinical trial investigational drug within 30 day prior treatment start . It permissable patient followup phase previous study . 2 . Patient receive systemic steroid therapy within three day prior first dose study treatment receive form immunosuppressive medication 3 . History allogeneic tissue/solid organ transplant 4 . History pneumonitis interstitial lung disease require oral i.v . steroid 5 . Radiotherapy target lesion ≤ 28 day prior first dose study treatment 6 . Major surgery ≤ 28 day prior first dose study treatment 7 . Minor surgery ( e.g . venous catheter ) ≤ 24 hour prior first dose study treatment 8 . Cardiovascular cerebrovascular disease clinical relevance : e.g . acute myocardial infarction stroke last 6 month , unstable angina , relevant unstable dysrhythmia ( control Tachyarrhythmia absoluta ( TAA ) allow ) . 9 . Wound heal disorder , active ulcus ventriculi/duodenal ulcer , bone fracture 10 . Known active Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) HIV infection 11 . Has active infection require systemic therapy . 12 . Patients active tuberculosis 13 . Prior therapy antiProgrammed cell death protein 1 ( antiPD1 ) , antiPDL1 , antiProgrammed cell deathligand 2 ( antiPDL2 ) , antiCD137 ( 41BB ligand , member Tumor Necrosis Factor Receptor ( TNFR ) family ) , antiCytotoxic Tlymphocyteassociated antigen4 ( antiCTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) 14 . Female patient pregnant breastfeeding , expect conceive father child study 120 day last administration study drug 15 . Indications neurological disease , may influence feasibility study may seriously disturb tolerability 16 . A diagnosis immunodeficiency patient receive chronic systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 17 . Patient prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . [ Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . ] 18 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 19 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 20 . Has receive live vaccine within 30 day prior first dose trial treatment . 21 . Has know hypersensitivity pembrolizumab insipients . 22 . Patient incarcerate involuntarily institutionalize court order authority § 40 Abs . 1 S. 3 Nr . 4 Arzneimittelgesetz ( AMG ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>